Latest Interstitial lung disease Stories
Guy Junker & Stan Savran Host Violet Rippy 5K Walk/Run for Second Year for the Coalition for Pulmonary Fibrosis PITTSBURGH, July 19, 2012 /PRNewswire-USNewswire/ -- Former Fox Sports Nets Co-Hosts Guy Junker and Stan Savran will join fellow Pittsburgh media celebrity Paul Alexander to host the Second Annual Violet Rippy 5K Walk/Run for Pulmonary Fibrosis. The event will be held at the North Shore Riverfront Park in Pittsburgh, PA on Saturday, August 11, 2012, and will benefit...
This international multicenter clinical trial studies an investigational new drug targeted at treating CF. During this trial, Intrinsic Imaging will evaluate Cystic Fibrosis lung pathophysiology to gain insights into the treatment’s effect on major manifestations of CF. Boston, MA (PRWEB) July 18, 2012 Intrinsic Imaging, an ISO 9001:2008 certified and GAMP 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials, announces today that it was...
BRISBANE, Calif., July 17, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter and first six months 2012 financial results prior to the open of the U.S. markets on Monday, July 23, 2012. A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time that same day. Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1 212-271-4651 (international),...
BRISBANE, Calif., July 9, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Jonathan A. Leff, M.D., Executive Vice President, Research and Development of InterMune, will present at the JMP Securities 7th Annual Healthcare Conference in New York on Thursday, July 12 at 12:30 p.m. EDT. To access a live audio webcast of any of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at...
Foundation Gives Its Condolences and Heartfelt Gratitude to the Family of Dr. I.M. Rosenzweig and Will Name Research Award in His Honor CHICAGO, June 29, 2012 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation is deeply saddened to announce the recent death of one of its co-founders, I.M. Rosenzweig, PhD. Mike, as he was known to all, lost his courageous battle with idiopathic pulmonary fibrosis (IPF) on June 23, 2012. Mike, who was a clinical psychologist,...
STOCKHOLM, June 28, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has included Esbriet® (pirfenidone) on Sweden's list of reimbursed drugs, making Esbriet the first medicine for the treatment of idiopathic pulmonary fibrosis (IPF) to be reimbursed in Sweden. Magnus Skold, Professor and Consultant at the Lung and Allergy Clinic at Karolinska University Hospital, said, "Esbriet is a clear step...
BRISBANE, Calif., June 14, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Wells Fargo Securities 2012 Healthcare Conference in Boston on Tuesday, June 19 at 3:00 p.m. EDT. To access a live audio webcast of any of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at...
Researchers at the University of Pittsburgh School of Medicine have identified an agent that in lab tests protected the skin and lungs from fibrosis, a process that can ultimately end in organ failure and even death because the damaged tissue becomes scarred and can no longer function properly. The findings were published today in Science Translational Medicine. There are no effective therapies for life-threatening illnesses such as idiopathic pulmonary fibrosis and systemic sclerosis,...
Key Peptide that Blocks Skin, Lung Fibrosis Could Improve Mortality Rates DANVERS, Mass., May 30, 2012 /PRNewswire-USNewswire/ -- A member of the Scleroderma Foundation's Board of Directors has led a team of researchers who have identified a peptide that can block fibrosis of the skin and lungs, according to a report published today. "Lung fibrosis currently is the number one cause of death in patients with scleroderma," said the report's senior author Carol A. Feghali-Bostwick,...
BRISBANE, Calif., May 30, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 33rd Annual Global Healthcare Conference at Rancho Palos Verdes, Calif. on Tuesday, June 5 at 10:40 a.m. PDT / 1:40 p.m. EDT. Mr. Welch will be joined in the presentation by Dr. Jonathan A. Leff, Executive Vice President, Research and Development for InterMune. To access a...
